EyePoint EYPT
NASDAQ EYPT
$4.58 +0.01 (+0.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

EyePoint (EYPT) Cash & Current Investments (2010 - 2026)

EyePoint (EYPT) posted Cash & Current Investments of $222.5 million for Q1 2026, down 27.29% sequentially from $306.1 million in Q4 2025, and down 30.06% YoY from $318.2 million in Q1 2025.

Analysis

EyePoint (EYPT) Cash & Current Investments (2010 - 2026) Analysis & Trends

EyePoint has reported Cash & Current Investments for 17 years, with the latest figure at $222.5 million in Q1 2026.

  • Quarterly Cash & Current Investments fell 30.06% year-over-year to $222.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $222.5 million (down 30.06% YoY) and the FY2025 annual result came in at $306.1 million, down 17.48% from the prior year.
  • Cash & Current Investments declined to $222.5 million in Q1 2026 per EYPT's latest filing, from $306.1 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $370.9 million in Q4 2024 and troughed at $122.5 million in Q1 2023.
  • A 5-year average of $229.8 million and a median of $222.5 million in 2026 frame the typical range for Cash & Current Investments.
  • The sharpest annual moves came in 2023 and 2024: Cash & Current Investments tumbled 35.81% in 2023, then jumped 144.44% in 2024.
  • Over 5 years, Cash & Current Investments stood at $144.6 million in 2022, then surged by 129.0% to $331.0 million in 2023, then advanced by 12.04% to $370.9 million in 2024, then fell by 17.48% to $306.1 million in 2025, then slipped by 27.29% to $222.5 million in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods registered $222.5 million, $306.1 million, and $204.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 7.85 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.99 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 5.18 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 5.14 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 5.10 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 3.31 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 836.99 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.16 Bn
10 EyePoint 398.53 Mn 218.06 Mn 507,000.00 180.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 180.47 Mn
Mar 31, 2026 222.55 Mn
Dec 31, 2025 306.09 Mn
Sep 30, 2025 204.02 Mn
Jun 30, 2025 255.73 Mn
Mar 31, 2025 318.19 Mn
Dec 31, 2024 370.91 Mn
Sep 30, 2024 253.79 Mn
Jun 30, 2024 280.25 Mn
Mar 31, 2024 299.35 Mn
Dec 31, 2023 331.05 Mn
Sep 30, 2023 136.04 Mn
Jun 30, 2023 142.54 Mn
Mar 31, 2023 122.48 Mn
Dec 31, 2022 144.56 Mn
Sep 30, 2022 157.26 Mn
Jun 30, 2022 171.17 Mn
Mar 31, 2022 190.78 Mn
Dec 31, 2021 211.59 Mn
Sep 30, 2021 119.71 Mn